Business Wire

MENTIMETER

14.3.2023 14:02:41 CET | Business Wire | Press release

Share
Mentimeter Announces Expansion of New North American Headquarters in Toronto as Company Scales for Growth

Mentimeter, the leading audience engagement platform, today announced the expansion of its North American headquarters based in Toronto, Canada, with the appointment of Tobias Porseurd to the role of North American General Manager. The news comes on the heels of the company’s successful Series C funding round in 2022, which aimed to support its growing organizational adoption in North America. Mentimeter reported a 281% year-over-year increase in customers and an 85% increase in revenues from the North American region in 2022. Currently, 30% of Mentimeter’s global customers are based in the U.S. and Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005002/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tobias Porseurd, North America General Manager at Mentimeter (Photo: Business Wire)

“Our substantial growth in North America signifies the staying power of Mentimeter as a post-pandemic workplace engagement tool that brings organizational value by powering better employee performance, productivity and informed decision-making,” said Johnny Warström, co-founder and CEO of Mentimeter. “We are thrilled that Tobias is leading our expansion efforts from Toronto as he brings proven success in scaling businesses that will allow our workforce to keep up with surging demand for our solution.”

To keep pace with rising demand, Mentimeter’s expansion is aimed at increasing headcount by 50%, led by Porseurd, who began his career at Mentimeter in May 2021 as the director of talent acquisition in Stockholm, Sweden. During that time, Porseurd was responsible for the strategic direction and management of the SaaS scale-up and ensuring Mentimeter continues to be a great place to work by helping attract employees to an inclusive, fun and collaborative environment. Through this role, Porseurd helped recruit over 100 employees in less than 12 months. Prior to joining Mentimeter, he was the co-founder and board member of Talent Eye, a talent recruitment company that provides solutions and interventions to employees. He has recently relocated to Toronto, Canada with his family.

“Mentimeter values creating meaningful connections with its customers, which begins with proximity,” said Porseurd. “As the North America General Manager, I intend to take a holistic approach to building and deepening North American customer relationships and empowering our client-base to create a positive, supportive and productive workforce. I’m also excited to expand our office by bringing in top talent in the area to provide our innovative offering across enterprises of all sizes as well as universities.”

About Mentimeter:

Mentimeter, a leading audience engagement platform, makes it easier to gather input and beautifully visualize it in real-time - transforming a passive audience into active contributors. Mentimeter is fundamentally changing the culture of presentations, lectures, and workshops in business and education from talking to listening. Whether on-site, remote, or hybrid, Mentimeter creates a unique, transparent, and engaging experience for everyone. Since launching in 2012, users have gathered opinions, questions, and thoughts through more than 35 million presentations utilizing the Mentimeter platform.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005002/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye